Aldosterone antagonist combined with a SGLT2 inhibitor versus SGLT2 inhibitor monotherapy: An updated meta‐analysis

Dr. Luís Mendonça has received consulting and speaker fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, and Novartis. Dr. João Sérgio Neves has received consulting and speaker fees from AstraZeneca, BIAL, Boehringer Ingelheim, Eli Lilly, and Novo Nordisk and speaker fees from Merck. Dr. Francisco Vasques-Nóvoa has received consulting or speaker fees from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi-Sankyo, Novartis, and Ultragenyx. Dr. Ana Rita Leite has received consulting fees from Bial. Dr. Pedro Marques has received speaker fees from Bial and Novartis. Dr. João Pedro Ferreira has received research support from Boehringer-Ingelheim, Novartis, AstraZeneca, Bayer, Abbott, Salamandra, and Bial. The peer review history for this article is available at https://www.webofscience.com/api/gateway/wos/peer-review/10.1111/dom.70363. This meta-analysis is based entirely on data from published randomized clinical trials. All source data are publicly available in the original articles cited in the manuscript. The compiled extraction sheets and analysis scripts can be obtained from the corresponding author upon reasonable request. Figure S1. Effect of MRA/ASi plus SGLT2i combination vs. SGLT2i alone on the studied outcomes by subgroups of HF status (HF or no HF). ASi, aldosterone synthase inhibitor; eGFR, estimated glomerular filtration rate; MRA, mineralocorticoid receptor antagonist; SBP, systolic blood pressure; UACR, urinary albumin-to-creatinine ratio. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.